GlassScriptPhysician profile
David M Koerner
NPI 1477528529
$4,755.99
in general payments reported to CMS, 2019-2025
23 companies · $385 in 2025
The $385 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,314 · 2020: $456 · 2021: $550 · 2022: $1,244 · 2023: $566 · 2024: $240 · 2025: $385.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,192.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,192.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,565.07 | 2019-2025 | Breztri, Airsupra, Farxiga |
| Novo Nordisk INC | $496.50 | 2019-2023 | Wegovy, Rybelsus, Ozempic |
| Abbvie INC. | $353.24 | 2021-2023 | |
| Kowa Pharmaceuticals America, INC. | $310.69 | 2019-2023 | Livalo, Seglentis |
| Glaxosmithkline, LLC. | $279.26 | 2019-2023 | Trelegy Ellipta |
| Lilly USA, LLC | $261.95 | 2019-2023 | Jardiance, Emgality, Mounjaro |
| Takeda Pharmaceuticals U.S.A., INC. | $226.96 | 2019-2023 | Trintellix |
| Merck Sharp & Dohme LLC | $220.70 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $195.54 | 2019-2023 | Trijardy Xr, Jardiance, Tradjenta |
| Amarin Pharma, INC. | $175.06 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $164.59 | 2019 | |
| Allergan, INC. | $110.19 | 2019-2020 | |
| Regeneron Healthcare Solutions, INC. | $67.45 | 2022 | |
| Amgen INC. | $63.71 | 2019-2020 | |
| Exact Sciences Corporation | $57.44 | 2023 | Cologuard Collection Kit |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $54.34 | 2019-2023 | Myrbetriq |
| Teva Pharmaceuticals USA, INC. | $33.42 | 2022-2023 | Ajovy |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $29.38 | 2023 | Xifaxan |
| Pfizer INC. | $26.82 | 2019-2021 | |
| Abbott Laboratories | $23.70 | 2022 | |
| Bausch Health US, LLC | $15.00 | 2022 | |
| Paratek Pharmaceuticals, INC. | $13.98 | 2021 | |
| Sanofi Pasteur INC. | $11.00 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Koerner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.